Table 2.

Complications after kidney biopsy in hospitalized patients with acute kidney disease

ComplicationN (% [95% CI of Proportion]) or Median (Interquartile Range)
Total159
Blood transfusion for biopsy-related bleedinga12 (8 [4 to 13])
Angiographic intervention to stop bleeding3 (2 [1 to 5])
Hematomab11 (7 [4 to 12])
Death in 30 dc4 (3 [1 to 6])
Reimaging after biopsy to check for bleedingd31 (20 [14 to 26])
Drop in hemoglobin, g/dl0.8 (0.4, 1.3)
 Hemoglobin drop >160 (39 [31 to 47])
 Hemoglobin drop >215 (10 [6 to 15])
  • Data presented as N [% (95% confidence interval of proportion)]. Fifteen (10%) patients experienced any complication defined as requirement of either an angiographic intervention or transfusion, or presence of hematoma.

  • a All transfusion events were reviewed to determine their relationship with the kidney biopsy procedure (see Supplemental Table 1).

  • b Hematoma described as medium, large, or at least 5 cm in any dimension.

  • c None of the deaths were due to a biopsy-related complication.

  • d Reimaging includes patients that required a second abdominal ultrasound or computed tomography imaging study to evaluate for bleeding within 7 d of a kidney biopsy.